Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Non-Rx drug exclusion from Canadian patented drug price controls bill sought by NDMAC.

This article was originally published in The Tan Sheet

Executive Summary

CANADIAN NON-Rx DRUG EXCLUSION FROM BILL C-91 SOUGHT BY NDMAC in a brief submitted March 27 to the Parliamentary Committee on Industry. The committee is reviewing Bill C-91, a 1993 act amending Canada's patent laws by establishing a Patented Medicine Prices Review Board (PMPRB) to set price controls for patented drugs, both prescription and nonprescription. Although the bulk of patented drugs in Canada are prescription, there is a movement under way in the country to expand the board's jurisdiction to nonpatented drugs, which would affect an additional 8,000-10,000 non-Rx products.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel